Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing bacteriophage therapies for serious bacterial infections. Its lead programs include AP-SA02 for Staphylococcus aureus bacteremia and AP-PA02 for chronic pulmonary infections caused by Pseudomonas aeruginosa. The company combines phage discovery, purification, and cGMP manufacturing capabilities at its Los Angeles-area McConnell Facility to support clinical development from early research through trial material production. Armata does not yet sell commercial products and remains dependent on clinical progress, regulatory milestones, and external funding.

1.19

1.19

— Armata Pharmaceuticals, Inc.
%
Clinical-stage phage therapeutics85% Investigational bacteriophage drug candidates being advanced through human trials for serious bacterial infections.
Grant and award-funded development15% Government and consortium-funded cost reimbursement tied to specific development programs such as AP-SA02.

Armata’s direct customers are not commercial end-users but research sponsors, clinical investigators, and ultimately...

  • Research sponsors and grant fundersprimary

    Organizations such as MTEC that reimburse development costs for AP-SA02 and support clinical advancement before commercialization.

  • Clinical trial investigators and sitesprimary

    Hospitals and research centers in the United States and Australia that enroll patients and generate clinical evidence for the phage programs.

  • Future hospital and specialist prescriberssecondary

    Infectious disease and pulmonary specialists who would use approved phage therapies for severe bacterial infections.

  • Patients with refractory bacterial infectionssecondary

    Patients with S. aureus bacteremia or chronic P. aeruginosa pulmonary disease who need alternatives to standard antibiotics.

Armata is headquartered in Los Angeles, California, and its core research and manufacturing operations are concentrated...

  • •Headquartered in Los Angeles, California
  • •McConnell Facility supports discovery, clinic transition, and cGMP manufacturing
  • •Clinical trial sites in the United States
  • •Clinical trial sites in Australia for AP-SA02
  • •U.S.-centric operations with limited international trial exposure
  • •Geography affects enrollment speed, regulatory coordination, and trial logistics

Armata’s strategy is to concentrate resources on a small number of phage programs with the clearest clinical and...

01
Complete AP-SA02 clinical developmentshort-term

AP-SA02 is the most advanced program and the clearest path to a registrational strategy in a high-unmet-need infection setting.

02
Demonstrate manufacturable, high-purity phage dosingshort-term

Repeat intravenous dosing and clinical scalability depend on reproducible purity and release processes.

03
Preserve cash and secure external fundingshort-term

The company has no product revenue and must fund ongoing R&D through grants, financing, or strategic arrangements.

04
Advance AP-PA02 as a second clinical assetmedium-term

A second validated program would diversify the pipeline and strengthen the platform thesis for phage therapeutics.

Armata faces the classic risks of a clinical-stage biotech company: clinical trial failure, regulatory setbacks, and...

high

Need for additional capital

The company has no commercial revenue and may need to raise funds to continue development, which could dilute shareholders or force program cuts.

Scope
All development programs
Materiality
high
high

Clinical development failure

AP-SA02 and AP-PA02 are still investigational, and negative efficacy or safety results would materially impair the platform thesis.

Scope
AP-SA02, AP-PA02
Materiality
high
high

Regulatory approval uncertainty

Even promising early data may not translate into FDA agreement on a registrational path or eventual approval.

Scope
FDA pathway for phage therapies
Materiality
high
medium

Manufacturing and scale-up complexity

Therapeutic phages require consistent purity and release standards, and any production issue could delay trials or commercialization.

Scope
cGMP clinical material
Materiality
medium
Grant and award revenue recognition
Can cause quarter-to-quarter variability unrelated to commercial demand
Fair value of convertible loan
Can materially distort earnings comparability
Research and development accruals
Affects operating loss timing
Stock-based compensation
Raises reported operating expenses and affects dilution analysis
Impairment and valuation estimates
Could create non-cash charges if development prospects weaken

Protara Therapeutics, Inc.

TARA · Biological Products, (No Diagnostic Substances)

Aprea Therapeutics, Inc.

APRE · Pharmaceutical Preparations

BiomX Inc.

PHGE · Biological Products, (No Diagnostic Substances)

FILANA THERAPEUTICS, INC.

FLNA · Pharmaceutical Preparations

Vera Therapeutics, Inc.

VERA · Pharmaceutical Preparations

LISATA THERAPEUTICS, INC.

LSTA · Pharmaceutical Preparations

: 11/08/2026